Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanced head and neck squamous cell carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.10.19
Views: 340

Prof Jean Bourhis - Lausanne University Hospital, Lausanne, Switzerland

Prof Jean Bourhis speaks to ecancer at ESMO 2019 in Barcelona about the results from the phase II GORTEC study, which compared concurrent high-dose cisplatin chemoradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck.

He explains the rationale for this study, which includes the synergy between debio 1143 and cisplatin chemoradiation observed in preclinical studies.

Prof Bourhis also outlines the design and results from this randomised, phase II trial, in which the progression-free survival was nearly doubled in patients treated with debio 1143 compared to placebo.

He concludes by stating that a larger trial testing the same hypothesis is needed to confirm these results of this trial and mentions these agents may have potential use in other cancer types also.


Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation